Last checked at 
LONDON (Alliance News) - Microsaic Systems PLC on Monday said it has developed new technology which could enable customers to achieve "significant costs and time savings" in the manufacture of biologics.
Shares in the company, which develops point-of-need mass spectrometry instruments, were trading 19% higher at 1.58 pence each.
Microsaic said it developed proof of concept workflows to analyse, in real-time, complex samples from bioreactors. The system was tested in an independent laboratory against traditionally accepted bioanalysers.
"Microsaic's MS technology detected metabolites not usually seen by traditional methods during the bio-manufacturing process," the company explained.
Chief Executive Officer Glenn Tracey added: "What we have demonstrated is the potential for our technology to replace very expensive analysers, which have been the mainstay of bio-analysis over time.
"As our technology can measure small and large molecules simultaneously, we can potentially replace workflows which use several analysis techniques costing hundreds of thousands of pounds each in capital expenditure."
